Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 3 Sarcoma 1 Recurrence 1 Neoplasm Metastasis 1 Meningeal Neoplasms 1 Inhibition, Psychological 1 Hereditary Sensory and Autonomic Neuropathies 1 Glioma 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Doxorubicin 27 pembrolizumab 24 Radiotherapy 20 Cyclophosphamide 18 Magnetic Resonance Spectroscopy 17 Specimen Handling 14 Nivolumab 14 Ifosfamide 13 Gemcitabine 13 Surgical Procedures, Operative 11 Biopsy 11 Radiation 10 Temozolomide 9 X-Rays 8 Ipilimumab 8 pazopanib 7 fludarabine 7 cabozantinib 7 Irinotecan 7 Blood Specimen Collection 7 tazemetostat 6 liposomal doxorubicin 6 Trabectedin 6 Surveys and Questionnaires 6 Phantoms, Imaging 6 olaparib 5 eribulin 5 atezolizumab 5 anlotinib 5 Vincristine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × AZD1390 × 1 year × Clear all

NCT05116254 2026-01-23

SADDRIN-1

The Netherlands Cancer Institute

Phase 1 Terminated

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡